AML Video Perspectives
Ghayas C. Issa, MD
Disclosures
Issa reports receiving research funding from Astex, Celgene, Cullinan Oncology, Kura Oncology, Merck, Novartis, NuProbe, and Syndax, and serving in consulting or in advisory roles for AbbVie, AstraZeneca, Kura Oncology, Novartis, Sanofi, and Syndax.
May 08, 2024
1 min watch
Save
VIDEO: Classifying emerging therapies for AML
Transcript
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
So I would classify them a little bit by mechanism. So there are immune therapies, and these would be largely based on type of therapies that would leverage the immune system to kill leukemia. And there are targeted therapies, these would be for specific mutations, and under that I would lump the menin inhibitors and maybe soon MDM two inhibitors or MDM two degraders. And then there are maybe new forms of chemotherapy that we're studying, or new form of kinase inhibitors that we're studying.
